Maddi Hebebrand, MC, Associate Editor

Discover essential career insights for early-career NP/PAs in dermatology, focusing on skill mastery, mentorship, and professional growth strategies.

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the transformative role of AI in dermatology with Nawar Shara, PhD, focusing on personalized skin care and patient safety.

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

Switching from dupilumab to upadacitinib significantly improves skin clearance and itch in patients with moderate to severe atopic dermatitis (AD).

The 2025 Inflammatory Skin Disease Summit (ISDS) unveils innovative therapies and immune profiling strategies, transforming the landscape of dermatological care.

James Del Rosso, DO, discusses innovative topical therapies for dermatologic conditions.

Obagi Medical's ALOHA Program launches Obagi saypha MagIQ, pioneering real-world evaluation of a new hyaluronic acid filler.

Recent research shows the long-term benefits and safety of low-level laser therapy for androgenetic alopecia.

Michael O'Donoghue, MD, discusses tailoring PDT for AK, emphasizing patient preferences and flexible treatment strategies.

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Public interest in GLP-1 weight loss medications surges, revealing concerns about aesthetic effects like "Ozempic face" and prompting new treatment strategies.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

Almirall initiates a pivotal phase 3 trial for lebrikizumab, targeting nummular eczema and aiming to enhance treatment options for this challenging condition.

Heap discusses promising phase 3 results for zasocitinib, an oral TYK2 inhibitor, showcasing its efficacy and safety in psoriasis therapy.

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Explore the complexities of managing hidradenitis suppurativa (HS) through real-world case studies moderated by Afsaneh Alavi, MD.

The National Psoriasis Foundation (NPF) redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

Zasocitinib emerges as a highly selective and potent allosteric tyrosine kinase 2 (TYK2) inhibitor, showing promise for treating immune-mediated inflammatory diseases.

Dupilumab demonstrates significant efficacy and safety in treating severe atopic dermatitis in children aged 6 months to 5 years, improving quality of life.

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.